Inflammation and insulin resistance play a major role in nonalcoholic fatty liver disease (NAFLD), and IL-12, a pro-inflammatory cytokine primarily secreted by macrophages, is elevated in obesity. Here, we examined the effects of acute treatment with IL-12 in vivo on glucose metabolism in male C57BL/6J mice. Mouse recombinant IL-12 (0.25 μg/hour) or saline (control) was infused for 4 hours, followed by insulin clamps in mice (n=5/group). Glucose infusion rates during clamps were significantly reduced in IL-12-treated mice, resulting in a 34% decrease compared to controls (Fig. 1-2). Basal hepatic glucose production (HGP) did not differ, but clamp HGP was significantly increased in IL-12-treated mice (Fig. 3). As a result, IL-12 treatment caused a 43% decrease in hepatic insulin action compared to controls (Fig. 4). These IL-12 effects were associated with a 4-fold increase in STAT4 tyrosine-phosphorylation (0.071±0.026 vs. 0.018±0.004 in controls) and a 47% decrease in IRS1 protein levels (0.264±0.044 vs. 0.496±0.112 in controls) in the liver. Attenuated liver IL-12 level was further associated with improved hepatic insulin action in diet-induced obese mice with conditional loss of IFNγ signaling in myeloid cells. CONCLUSION: Our findings identify IL-12 as a novel cytokine regulating obesity-mediated insulin resistance and inflammation in the liver and a potential therapeutic target to treat NAFLD.


R.H.Friedline: None. M.Albusharif: None. A.M.Kim: None. L.H.Kim: None. N.M.Baez torres: None. L.A.Tauer: None. X.Hu: None. J.K.Kim: None.


National Institutes of Health (5U2CDK093000)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at